Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record.

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at Eight Years by 'Nolvadex'/Adjuvant Trial Organisation.

Open access
Analysis at Eight Years by 'Nolvadex', Adjuvant Trial Organisation.·1988·British Journal of Cancer

Abstract

At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage, grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and suggests that more prolonged treatment might further improve results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.1988.138

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 250

Metadata

Authors
'Nolvadex', A. A. E. Y. B., & Adjuvant Trial Organisation.
Venue
British Journal of Cancer
Published
1988-12
Volume
57
Issue
6
Pages
608-611
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4246467214
Cited by
250
References
0
FWCI
11.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at Eight Years by 'Nolvadex'/Adjuvant Trial Organisation. https://app.cochat.ai/papers/10.1038/bjc.1988.138
The paper
'Nolvadex', A. A. E. Y. B., & Adjuvant Trial Organisation. (1988). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at Eight Years by 'Nolvadex'/Adjuvant Trial Organisation. British Journal of Cancer. https://doi.org/10.1038/bjc.1988.138

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.